HBOT and Amputation Reduction

Understanding When Hyperbaric Oxygen May Support Limb Salvage and Why It Must Remain Part of a Multidisciplinary Strategy

Preventing amputation is one of the most compelling goals in wound care, vascular medicine, trauma surgery, podiatry, and hyperbaric medicine. Limb loss can profoundly affect mobility, independence, employment, rehabilitation needs, and quality of life.

Hyperbaric oxygen therapy, commonly abbreviated as HBOT, may contribute to amputation reduction in selected patients whose limbs are threatened by hypoxic wounds, acute traumatic ischemia, severe tissue injury, or compromised reconstruction. It is not a universal limb-salvage treatment and should never be presented as an alternative to revascularization, surgical source control, pressure relief, or appropriate amputation when an unsalvageable limb threatens the patient’s life.

The most accurate clinical position is that HBOT may improve tissue preservation and wound healing in carefully selected patients. Whether those effects reliably reduce major amputation remains dependent on the diagnosis, severity, timing, standard care, and quality of the available evidence.

Amputation Reduction Is a System Outcome

An amputation is rarely caused by insufficient tissue oxygen alone. Most threatened limbs involve several interacting problems, such as:

• Peripheral arterial disease
• Neuropathy
• Infection
• Osteomyelitis
• Tissue necrosis
• Repetitive pressure
• Severe edema
• Traumatic vascular injury
• Delayed presentation
• Metabolic disease
• Inadequate access to specialty care

The CDC reports that lower-limb amputations are increasing in the United States and that complications associated with diabetes account for a substantial share of these procedures. It also identifies vascular disease, neuropathy, infection, delayed wound recognition, and unequal access to care as important contributors. (CDC)

This means no single technology can be credited with reducing amputations across an entire population. Effective limb preservation generally requires coordinated vascular assessment, infection control, debridement, offloading, metabolic management, reconstructive care, rehabilitation, and selected adjunctive treatments.

HBOT should be understood as one component of that system.

How HBOT May Support Limb Preservation

During HBOT, the patient breathes oxygen while exposed to increased atmospheric pressure. This substantially increases arterial oxygen tension and the amount of oxygen dissolved directly in plasma.

Oxygen-rich plasma can diffuse farther from functioning capillaries into hypoxic tissue. This may be helpful when edema, inflammation, microvascular injury, or impaired red blood cell passage limits ordinary oxygen delivery.

Potentially relevant effects include:

• Increased oxygen availability in viable hypoxic tissue
• Support for fibroblast activity and collagen deposition
• Promotion of angiogenic signaling
• Improved oxygen-dependent leukocyte activity
• Reduction of selected forms of edema
• Modulation of ischemia-reperfusion injury
• Support for demarcation and preservation of marginal tissue

These effects can improve the environment in which tissue heals, but they require some remaining circulation. HBOT cannot deliver an adequate oxygen dose to tissue with no functional blood supply.

It also cannot restore tissue that is already irreversibly necrotic.

Diabetic Foot Ulcers Are the Primary Amputation-Reduction Population

Most discussion of HBOT and amputation reduction concerns diabetes-related foot ulcers.

Diabetes can increase limb-loss risk through the combined effects of neuropathy, peripheral arterial disease, impaired healing, infection, and delayed recognition of tissue damage. A small wound can progress into a deep ulcer, abscess, osteomyelitis, gangrene, or systemic infection when these problems are not corrected promptly. (CDC)

HBOT is not indicated for every diabetic foot ulcer. The strongest clinical and coverage frameworks focus on advanced, limb-threatening wounds that have not responded adequately to comprehensive standard care.

Medicare currently covers adjunctive HBOT for a diabetes-related lower-extremity wound when all three of the following conditions are met:

1. The patient has type 1 or type 2 diabetes.
2. The wound is classified as Wagner grade III or higher.
3. The wound has failed an adequate course of standard therapy.

Coverage begins only after at least 30 days without measurable healing and requires continued standard wound management during the HBOT course. (Centers for Medicare & Medicaid Services)

Wagner Grade Matters, but It Is Not the Entire Assessment

The Wagner system describes diabetic foot ulcer depth and the presence of deeper infection or gangrene.

In simplified terms:

• Grade I involves a superficial ulcer.
• Grade II extends into deeper structures.
• Grade III involves deep infection, abscess, or osteomyelitis.
• Grade IV involves localized gangrene.
• Grade V involves extensive gangrene of the foot.

Higher grades generally indicate greater limb threat, but Wagner classification does not describe every factor influencing salvage. It does not fully capture ischemia severity, infection severity, wound location, tissue perfusion, patient frailty, renal disease, or reconstructive options.

The decision to use HBOT should therefore combine wound grade with vascular, surgical, infectious, and functional assessments.

Current Guidelines Are Supportive but Cautious

The 2023 International Working Group on the Diabetic Foot guideline conditionally recommends considering systemic HBOT for neuro-ischemic or ischemic diabetes-related foot ulcers when standard care alone has failed and the resources needed to provide treatment already exist. The recommendation is based on low-certainty evidence.

Importantly, the guideline found that better-quality studies suggested possible benefits in wound healing and ulcer-area reduction, but it concluded that strong evidence of amputation prevention was lacking. It also noted major differences among studies in ischemia severity, outcome definitions, follow-up periods, and treatment methods. (IWGDF Guidelines)

Earlier UHMS guidance was more favorable, suggesting HBOT for Wagner grade III or higher wounds that failed to improve after 30 days of standard care, with the objective of reducing major amputation and incomplete healing. (Guideline Central)

These positions are not necessarily contradictory. They reflect different evidence-review methods, publication dates, and thresholds for making recommendations.

Why Meta-Analyses Reach Different Conclusions

Several meta-analyses have reported lower amputation rates or higher healing rates with adjunctive HBOT. A 2024 review organized by Wagner grade reported lower minor amputation rates in grade III ulcers and lower major amputation rates in grade IV ulcers. (PubMed Central (PMC))

Other analyses have also concluded that HBOT may reduce major amputation when added to standard care. (PubMed Central (PMC))

These findings are encouraging, but they should not be interpreted as definitive proof that HBOT independently prevents amputation in routine practice. Meta-analysis cannot fully correct weaknesses in the studies it combines.

Common limitations include:

• Small study populations
• Inconsistent wound classifications
• Variable ischemia severity
• Different HBOT pressures and schedules
• Incomplete reporting of revascularization
• Differences in offloading and infection control
• Variation in how amputation was defined
• Limited blinding
• High risk of selection bias
• Short or inconsistent follow-up

The IWGDF guideline therefore reached a more restrained conclusion despite reviewing multiple trials. It found possible healing benefits but insufficient reliable evidence for amputation reduction as a distinct outcome.

Major and Minor Amputation Should Not Be Combined Carelessly

Amputation studies frequently distinguish between minor and major procedures.

A minor amputation may remove a toe, ray, or portion of the foot while preserving a functional limb. A major amputation generally occurs at or above the ankle and carries greater implications for mobility and prosthetic rehabilitation.

These outcomes should not automatically be treated as equivalent.

A limited toe or ray amputation may be part of successful limb salvage when it removes infected or nonviable tissue and allows the remaining foot to heal. Avoiding every minor amputation is not always an appropriate clinical objective.

A more meaningful goal may be:

• Preventing progression to below-knee or above-knee amputation
• Preserving a plantigrade, functional foot
• Maintaining the ability to transfer or walk
• Limiting the level of tissue removal
• Achieving durable wound closure
• Preventing recurrent sepsis or hospitalization

Research reports should identify the level and purpose of amputation rather than presenting all procedures as the same adverse outcome.

Revascularization Comes Before Hyperbaric Treatment

A threatened diabetic limb requires vascular assessment. This may include pulse examination, ankle pressures, toe pressures, Doppler waveforms, transcutaneous oxygen testing, duplex imaging, CT angiography, conventional angiography, or another appropriate study.

When significant correctable arterial disease is present, endovascular or open revascularization may be required.

Global vascular guidelines emphasize revascularization planning, medical therapy, surveillance, and multidisciplinary care for chronic limb-threatening ischemia. They state that the effectiveness of nonrevascularization therapies, including HBOT, has not been established as a replacement for restoring blood flow. (PubMed)

HBOT should not be used to postpone vascular consultation or create the appearance that an ischemic wound is being treated while the underlying arterial obstruction remains unaddressed.

The treatment may become relevant after:

• Revascularization has restored the best achievable inflow
• No additional vascular intervention is technically possible
• Residual microvascular hypoxia continues to threaten healing
• The patient otherwise meets a recognized indication

CMS similarly requires assessment and correction of vascular problems when possible as part of standard diabetic wound care before and during HBOT. (Centers for Medicare & Medicaid Services)

Infection Requires Source Control

Deep infection, abscess, necrotizing tissue, and osteomyelitis are major drivers of amputation.

HBOT may support leukocyte activity and tissue oxygenation, but it cannot drain an abscess, remove infected bone, or debride necrotic tissue.

Limb-salvage care may require:

• Urgent incision and drainage
• Surgical debridement
• Bone resection
• Culture-directed antimicrobial therapy
• Removal or revision of infected hardware
• Staged reconstruction
• Minor amputation to control infection

The IWGDF infection guideline advises against using HBOT when the sole objective is treatment of a diabetes-related foot infection because evidence for infection control itself is limited. The potential indication is the qualifying wound and its healing environment, not infection in isolation. (IWGDF Guidelines)

A patient with advancing sepsis or necrotizing infection needs surgery and resuscitation before chamber scheduling.

Offloading Is a Limb-Salvage Intervention

Neuropathic foot wounds often remain open because the injured area continues to bear pressure during standing and walking.

HBOT cannot compensate for persistent mechanical trauma. Even a well-oxygenated wound may fail when it is repeatedly compressed or sheared.

The care plan may require:

• Total-contact casting
• A removable cast walker
• Custom footwear
• Postoperative offloading
• Assistive devices
• Activity modification
• Correction of deformity in selected patients

CMS includes appropriate offloading among the standard-care requirements that must continue during HBOT. (Centers for Medicare & Medicaid Services)

Poor adherence should be addressed compassionately. Transportation, work, caregiving responsibilities, housing conditions, cognitive impairment, and the practical difficulty of using an offloading device may all affect adherence.

Acute Trauma Creates a Different Limb-Salvage Pathway

HBOT may also support amputation reduction in selected crush injuries, severe open fractures, compartment syndromes, replantations, and acute traumatic peripheral ischemia.

The treatment rationale involves increasing oxygen delivery to marginally perfused tissue, reducing edema, and limiting secondary ischemia-reperfusion injury. As in chronic wounds, HBOT must not delay hemorrhage control, vascular repair, fracture stabilization, fasciotomy, or debridement.

The international HOLLT randomized trial studied HBOT in severe lower-limb trauma. The combined primary outcome of acute infection or necrosis was lower in the HBOT group but did not reach statistical significance. Tissue necrosis considered separately occurred less frequently with HBOT, while acute infection did not differ significantly. (PubMed Central (PMC))

The trial supports a potential tissue-preservation benefit, but it was not definitive evidence that HBOT reduces traumatic amputation across all injury patterns. Injury severity, vascular disruption, contamination, reconstruction, and timing remain decisive.

Medicare recognizes acute traumatic peripheral ischemia and crush injuries as covered indications when function, limb, or life is threatened. (Centers for Medicare & Medicaid Services)

Compromised Reconstructions May Affect Amputation Risk

A failed graft, flap, replantation, or soft-tissue reconstruction can expose bone, vessels, tendon, hardware, or a previously closed amputation site. Loss of coverage may convert a salvageable limb into one requiring more extensive tissue removal.

HBOT may be considered when reconstructive tissue is hypoxic but viable after mechanical and vascular causes have been corrected.

The surgeon must first evaluate for:

• Arterial or venous thrombosis
• Pedicle kinking
• Hematoma
• Seroma
• Excessive pressure
• Infection
• Graft displacement
• Inadequate recipient-bed preparation

Medicare covers preparation and preservation of compromised skin grafts but not HBOT for the primary management of ordinary wounds. (Centers for Medicare & Medicaid Services)

Successful preservation of coverage may indirectly reduce amputation risk, but the clinical endpoint should be documented as graft or flap salvage rather than assuming that every successful reconstruction prevented a major amputation.

Patient Selection Determines Whether HBOT Can Help

The best candidates have a defined oxygen-responsive problem and enough viable tissue remaining to change the outcome.

Features that may support referral include:

• An advanced diabetes-related foot ulcer
• Ischemic or neuro-ischemic wound physiology
• Failure of comprehensive standard care
• Corrected or maximally treated arterial disease
• Adequate source control
• A salvageable foot or limb
• A realistic functional objective
• Ability to complete a prolonged treatment schedule

HBOT is less likely to change the outcome when:

• The limb is irreversibly necrotic
• Uncontrolled sepsis requires immediate amputation
• Revascularization is needed but has not been pursued
• Mechanical pressure remains uncorrected
• The wound is superficial and otherwise healing
• The patient cannot complete treatment safely
• Continued limb salvage would leave a painful, nonfunctional extremity
• Treatment would delay a necessary operation

Limb preservation should not become an absolute goal when amputation offers the safest path to infection control, wound closure, pain relief, or functional rehabilitation.

Treatment Requires Repeated Exposure

A chronic wound course commonly involves daily treatment, often five days per week, over several weeks. The pressure, duration, oxygen periods, air breaks, and total number of treatments should be prescribed by a qualified hyperbaric physician.

The course should not be treated as an automatic block of visits.

Clinical reassessment should consider:

• Wound dimensions
• Tissue quality
• Granulation
• Drainage
• Necrosis
• Infection
• Vascular status
• Offloading adherence
• Need for further surgery
• Overall functional plan

CMS requires reassessment at least every 30 days and does not support continued coverage when measurable healing has not occurred during a treatment interval. (Centers for Medicare & Medicaid Services)

A wound that continues to deteriorate needs diagnostic and surgical reassessment, not simply more chamber sessions.

Amputation-Free Survival Is a Better Long-Term Measure

A program should not evaluate success only by asking whether an amputation occurred during the HBOT course.

More meaningful measures include:

• Major amputation-free survival
• Time to durable wound closure
• Recurrence after healing
• Rehospitalization
• Repeat debridement
• Functional walking status
• Preservation of an independently usable limb
• Mortality
• Patient-reported quality of life

A limb may remain attached but provide little function, remain chronically infected, or require repeated hospitalization. Conversely, a minor amputation may allow durable healing and preserve mobility.

Outcome reporting should reflect these distinctions.

Risks and Treatment Burden Matter

HBOT is generally well tolerated in appropriately selected patients, but it is not risk free.

Potential adverse effects include:

• Middle-ear or sinus barotrauma
• Claustrophobia
• Blood glucose changes
• Temporary visual changes
• Pulmonary pressure injury
• Rare oxygen-induced seizure

Patients with advanced diabetic wounds may also have heart failure, kidney disease, frailty, pulmonary disease, limited mobility, or unstable glucose levels. The IWGDF guideline specifically notes that comorbidity and frailty can affect suitability for treatment.

The practical burden can be considerable. Daily transportation, time away from work or caregiving, dressing coordination, and prolonged offloading can make completion difficult. These barriers should be assessed before treatment begins.

Limb Salvage Requires Equity and Early Access

Amputation risk is influenced by more than biology.

The CDC reports substantial geographic and racial differences in diabetes-related lower-limb amputations. It also identifies transportation, income, health literacy, access to care, and other social determinants as contributors to unequal outcomes. (CDC)

A technically advanced HBOT program cannot reduce population-level amputations when patients reach vascular, podiatric, or wound specialists only after extensive gangrene or infection has developed.

Effective prevention requires:

• Early foot screening
• Rapid referral for new ulcers
• Access to vascular assessment
• Timely infection treatment
• Affordable offloading
• Transportation support
• Patient education
• Coordination across specialties

HBOT should be added to this pathway rather than used as a substitute for it.

A Balanced Clinical Interpretation

The evidence supports neither of two extreme claims.

It is inaccurate to say that HBOT has no potential role in amputation reduction. Several randomized studies, clinical guidelines, and meta-analyses suggest that selected advanced diabetic wounds and traumatic ischemic injuries may benefit from adjunctive treatment. (PubMed Central (PMC))

It is also inaccurate to claim that HBOT reliably prevents amputation in every patient with a diabetic wound or threatened limb. The current IWGDF guideline considers the certainty of evidence low and states that strong evidence of amputation prevention is lacking.

The most defensible position is selective use.

HBOT may improve the probability of limb preservation when:

1. The diagnosis is appropriate.
2. The limb remains salvageable.
3. Blood flow has been evaluated and optimized.
4. Infection and necrosis have been treated surgically.
5. Offloading and metabolic care are active.
6. Treatment begins before irreversible tissue loss.
7. Progress is measured objectively.
8. The clinical team is willing to stop or revise the plan when benefit is not occurring.

HBOT does not save limbs by itself. It may strengthen a coordinated limb-preservation strategy by supporting viable hypoxic tissue during the period in which vascular, surgical, infectious, and wound-care interventions are working.